Concepedia

Hiroomi Tada

HT

10

Publications

1.2K

Citations

10

H-Index

1987

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

GlaxoSmithKline (Netherlands)

University of Pennsylvania

Hiroomi Tada is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pathology.

Top concepts

MedicineOncologyPathologyPharmacotherapyRadiation OncologyPharmacologyTumor BiologyCancer BiologyCancer ResearchMolecular Diagnostics

Publications per year

1987–2022

10

Publications

10

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

Roy S. Herbst, Yan Sun, Wilfried Eberhardt et al. · The Lancet Oncology · 2010 · 417 citations · Full text

Second-line Treatment, Oncology, Metronomic Therapy +10

Pigmented epithelioid melanocytoma

Jon R. Ward, Stephen Brady, Hiroomi Tada et al. · International Journal of Dermatology · 2006 · 206 citations

Biopsy Specimen, Tumoral Pathology, Skin Cancer +13

KOC (K Homology Domain Containing Protein Overexpressed in Cancer)

Rhonda K. Yantiss, Bruce A. Woda, Gary R. Fanger et al. · The American Journal of Surgical Pathology · 2005 · 163 citations

Tumor Biology, Oncology, Pancreatic Cancer +14

Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors

Antoinette R. Tan, Darlene Gibbon, Mark N. Stein et al. · Cancer Chemotherapy and Pharmacology · 2013 · 105 citations

Oncology, Solid Tumors, Pharmacology +4

<i>HLA-B</i> *57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer

Chun‐Fang Xu, Toby Johnson, Xiaojing Wang et al. · Clinical Cancer Research · 2015 · 95 citations · Full text

Rows per page

1–5 of 10